---
id: 237
title: COVID-19 (SARS-CoV-2 Infection)
category: clinical_syndromes
subcategory: viral
tags: [COVID-19, SARS-CoV-2, nirmatrelvir-ritonavir, Paxlovid, dexamethasone, remdesivir]
difficulty: high
---

## Question

How is COVID-19 managed? Use **"High-Risk Outpatient: Nirmatrelvir-Ritonavir × 5d, Severe/Hospitalized: Dexamethasone + Remdesivir"** framework.

## Answer

### **Clinical Presentation:**

**Spectrum:**
- **Asymptomatic** (20-40% of infections)
- **Mild-moderate** (80% of symptomatic)
- **Severe** (15% hospitalized)
- **Critical** (5% ICU, mechanical ventilation)

**Common Symptoms:**
- **Fever, cough** (dry initially)
- **Fatigue, myalgias**
- **Loss of taste/smell** (anosmia, ageusia) - highly specific for COVID-19
- **Sore throat, rhinorrhea**
- **Shortness of breath** (if lower respiratory involvement)
- **GI symptoms** (nausea, vomiting, diarrhea) - 10-20%

**Severe COVID-19:**
- **Hypoxemia** (SpO₂ <94% on room air)
- **Respiratory distress** (RR >30)
- **Bilateral infiltrates** (>50% lung involvement on imaging)

**Critical COVID-19:**
- **ARDS, shock, multiorgan failure**

### **Diagnosis:**

**Nucleic Acid Amplification Test (NAAT, PCR):**
- **Gold standard** (sensitivity >95%)
- **Nasopharyngeal swab** (preferred)

**Rapid Antigen Test:**
- **Lower sensitivity** (70-85%), high specificity (>95%)
- **Best if symptomatic** (higher viral load)
- **Negative does NOT rule out** (repeat or confirm with NAAT if high suspicion)

### **Treatment:**

**Outpatient (Mild-Moderate, High-Risk):**

**Indications for Treatment:**
- **High-risk for progression** to severe disease:
  - Age ≥65y
  - Immunocompromised
  - Chronic conditions (lung, heart, kidney, diabetes, obesity)
  - Unvaccinated

**First-Line (If Within 5 Days of Symptom Onset):**
- **Nirmatrelvir-ritonavir (Paxlovid) 300mg/100mg PO BID × 5 days**
  - **Nirmatrelvir:** Protease inhibitor
  - **Ritonavir:** CYP3A4 inhibitor (boosts nirmatrelvir levels)
  - **Check drug interactions** (ritonavir interacts with many medications)
  - **Dose adjust if CrCl 30-60:** 150mg/100mg BID
  - **Avoid if CrCl <30**
  - **"Paxlovid rebound":** 10-15% have symptom recurrence after completing course (usually mild, self-limited)

**Alternative:**
- **Remdesivir 200mg IV day 1 → 100mg IV days 2-3** (3-day course, outpatient infusion)
- **Molnupiravir 800mg PO BID × 5 days** (less effective than nirmatrelvir-ritonavir, use only if others unavailable)

**Monoclonal Antibodies:**
- **NOT currently recommended** (resistance with circulating variants)

**Inpatient (Severe/Critical COVID-19):**

**Oxygen Requirement:**

**Severe (Supplemental O₂, Not Intubated):**
- **Dexamethasone 6mg PO/IV daily × 10 days** (or until discharge)
  - **Reduces mortality** (NNT ~9 for mortality benefit)
- **+ Remdesivir 200mg IV day 1 → 100mg IV days 2-5** (5-day course)
  - **Shortens time to recovery** (especially if started early)

**Critical (High-Flow O₂, NIPPV, Mechanical Ventilation, ECMO):**
- **Dexamethasone 6mg PO/IV daily × 10 days**
- **+ Remdesivir** (consider, benefit less clear if intubated)
- **+ Baricitinib 4mg PO/IV daily × 14 days** (or until discharge)
  - **JAK inhibitor** (anti-inflammatory)
  - **Reduces mortality** when added to dexamethasone (especially if high O₂ requirement)
- **+ Tocilizumab 8 mg/kg IV × 1** (may repeat × 1 if no improvement)
  - **IL-6 receptor antagonist**
  - **Consider if:** Rapidly increasing O₂ requirement, high inflammatory markers (CRP >75 mg/L)

**Do NOT Use Corticosteroids if:**
- **Mild disease, no oxygen requirement** (may prolong viral shedding, no benefit)

**Do NOT Use:**
- **Ivermectin, hydroxychloroquine** (no proven benefit, NOT recommended)

### **Supportive Care:**

**Prone Positioning:**
- **Awake prone positioning** (non-intubated patients with hypoxemia) - improves oxygenation

**Anticoagulation:**
- **Prophylactic-dose heparin** (all hospitalized patients, unless contraindicated)
- **Therapeutic anticoagulation:** If VTE diagnosed (high incidence in COVID-19, 10-20%)

**Empiric Antibiotics:**
- **Do NOT routinely give** (bacterial co-infection rare, <5%)
- **Consider if:** Severe illness, concern for bacterial superinfection

### **Post-Acute Sequelae of COVID-19 (PASC, "Long COVID"):**

**Definition:**
- **Persistent symptoms >4 weeks** after acute infection
- **10-30%** of COVID-19 patients

**Common Symptoms:**
- **Fatigue** (most common)
- **Dyspnea, cough**
- **Cognitive impairment** ("brain fog")
- **Post-exertional malaise**
- **Dysautonomia** (POTS)

**Management:**
- **Supportive care** (no specific treatment)
- **Gradual return to activity** (pacing)
- **Multidisciplinary care** (pulmonary, cardiology, neurology as needed)

### **Prevention:**

**Vaccination:**
- **Primary series + boosters** (updated formulations annually)
- **Most effective prevention**

**Pre-Exposure Prophylaxis (Immunocompromised):**
- **Tixagevimab-cilgavimab** (Evusheld) - NO LONGER EFFECTIVE (resistance with current variants)

**Post-Exposure Prophylaxis:**
- **NOT routinely recommended** (limited efficacy with current variants)

### **Prognosis:**

**Mortality:**
- **Overall:** 1-2% (varies by variant, vaccination status, age)
- **Hospitalized:** 10-20%
- **ICU/mechanical ventilation:** 30-50%

**Risk Factors for Severe Disease:**
- **Age ≥65y**
- **Obesity** (BMI ≥30)
- **Chronic conditions** (diabetes, heart, lung, kidney disease)
- **Immunosuppression**
- **Unvaccinated**

## Key Points

### **Outpatient High-Risk = Nirmatrelvir-Ritonavir:**
- **Paxlovid 300mg/100mg PO BID × 5 days** (within 5 days onset)
- **Check drug interactions** (ritonavir)

### **Hospitalized Severe = Dexamethasone + Remdesivir:**
- **Dexamethasone 6mg daily × 10 days** (reduces mortality)
- **+ Remdesivir 200mg day 1 → 100mg days 2-5**

### **Critical = Add Baricitinib or Tocilizumab:**
- **Baricitinib 4mg daily × 14 days** (with dexamethasone)
- **Tocilizumab 8 mg/kg IV × 1** (if rapidly worsening, high CRP)

### **Do NOT Use Steroids if Mild:**
- **Only if oxygen requirement** (may harm if mild disease)

### **Long COVID (10-30%):**
- **Fatigue, dyspnea, brain fog** (persistent >4 weeks)
- **Supportive care** (no specific treatment)

### **Clinical Pearls:**
- **Outpatient high-risk:** Nirmatrelvir-ritonavir (Paxlovid) 300mg/100mg BID × 5 days (within 5 days)
- **Severe (O₂ requirement):** Dexamethasone 6mg × 10 days + remdesivir
- **Critical (high-flow/vent):** Add baricitinib 4mg daily OR tocilizumab
- **Do NOT use steroids** if no O₂ requirement
- **Long COVID:** Fatigue, brain fog (10-30%, supportive care)
- **Prophylactic anticoagulation** (all hospitalized)

## Sources

- [NIH: COVID-19 Treatment Guidelines 2024]
- [IDSA: COVID-19 Management 2024]

## Media

N/A
